IOVA

Iovance Biotherapeutics, Inc. Common Stock

8.04

USD

+0.30

+3.88%

Nov 06, 15:59 UTC -5

Closed

Pre-Market

8.00

-0.04

-0.56%

Iovance Biotherapeutics, Inc. Common Stock (IOVA) Profile

Iovance Biotherapeutics, Inc. Common Stock Profile

About

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.

Info & Links

CEO

Frederick G. Vogt

Headquarters

825 INDUSTRIAL ROAD, SUITE 100
SAN CARLOS, CA 94070, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

975

Iovance Biotherapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

3.70B

Enterprise Value

3.64B

Enterprise Value/EBITDA(ttm)

-18.80

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

9.61

Price to Book(mrq)

4.95

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

51.85%

Operating Margin(ttm)

-58.20%

Profit Margin(ttm)

-64.88%

Return on Equity(ttm)

-30.68%

Return on Invested Capital(ttm)

-30.41%

Return on Assets(ttm)

-24.02%

Income Statement

Revenue(ttm)

378.98M

Revenue Per Share(ttm)

0.82

Gross Profit(ttm)

201.75M

EBITDA(ttm)³

-193.70M

Net Income Available to Common(ttm)

-220.53M

Diluted EPS(ttm)

-0.53

Share Statistics

Beta (5Y Monthly)

0.88

52-Week Change

249.57%

S&P 500 52-Week Change

14.38%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

462.66M

Dividend Yield

0.00%

Float⁴

417.64M

% Held by Insiders

7.80%

% Held by Institutions

77.03%

Balance Sheet

Total Cash(mrq)

376.32M

Total Cash Per Share(mrq)

0.81

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

5.20%

Quick Ratio(mrq)

3.82%

Book Value Per Share(mrq)

1.76

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.30

Free Cash Flow(ytd)

-154.17M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.